BASi Files Amended Form 10-K and 10-Q with the SEC

  BASi Files Amended Form 10-K and 10-Q with the SEC

Business Wire

WEST LAFAYETTE, Ind. -- October 11, 2013

Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it has filed
amended quarterly and annual reports with the SEC, including Form 10-K/A for
the fiscal years ended September 30, 2011 and 2012, Form 10-Q/A for the three
months ended December 31, 2011 and 2012, and Form 10-Q/A for the three and six
months ended March 31, 2012 and 2013.

The Company currently expects to file with the SEC its Form 10-Q for the three
and nine months ended June 30, 2013 by October 18, 2013.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit for more
about BASi.

This release contains forward-looking statements that are subject to risks and
 uncertainties including, but not limited to, risks and uncertainties related
    to changes in the market and demand for our products and services,the
    development, marketing and sales of products and services, changes in
 technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
                             Exchange Commission.


Company Contact:
Bioanalytical Systems, Inc.
Jacqueline Lemke
President & CEO and CFO
Agency Contact:
Berkman Associates
Neil Berkman
Press spacebar to pause and continue. Press esc to stop.